莱美药业公告称，其控股子公司海南莱美医疗器械有限公司收到海南省药监局颁发的两项《医疗器械注 册证》，产品为医用电子内窥镜图像处理器（型号：TS－02）和电子支气管镜（型号：LM－01），有 效期均为2025年11月17日至2030年11月16日。这两款产品将相互配套使用，有利于临床对患者病症的判 断及治疗。此次获证将丰富公司产品种类，提升综合竞争力，但产品实际销售受市场推广效果影响，对 业绩的具体影响尚无法预测。 ...

Group 1 - The core point of the article is that Lai Mei Pharmaceutical has received two medical device registration certificates from the Hainan Provincial Drug Administration for its subsidiary, Hainan Lai Mei Medical Equipment Co., Ltd., including a "medical electronic endoscope image processor" [1] Group 2 - The price of Feitian Moutai has dropped by 43% over the past two years, with the latest price at 1520 yuan, indicating a significant decline in the profitability of distributors [1]

Core Viewpoint - Laime Pharmaceutical (300006.SZ) announced that its subsidiary, Hainan Laime Medical Devices Co., Ltd., received two Medical Device Registration Certificates from the Hainan Provincial Drug Administration for its medical electronic endoscope image processor and electronic bronchoscope, enhancing its product offerings and competitive edge in the market [1] Group 1 - The medical electronic endoscope image processor and electronic bronchoscope are developed by Laime Medical Devices, allowing direct observation of patient images, which aids in clinical diagnosis and treatment [1] - The certification of these products will further enrich the company's medical device product range, meeting diverse market demands [1] - This development is expected to positively impact the company's future operations and overall competitiveness [1]

本次获证产品的实际销售情况取决于未来市场推广效果，目前尚无法预测其 对公司未来业绩的具体影响。敬请广大投资者谨慎决策，注意投资风险。 三、备查文件 证券代码：300006 证券简称：莱美药业 公告编号：2025-058 重庆莱美药业股份有限公司 关于控股子公司获得医疗器械注册证的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈 述或重大遗漏。 近日，重庆莱美药业股份有限公司（以下简称"公司"）控股子公司海南莱美 医疗器械有限公司（以下简称"莱美医疗器械"）收到海南省药品监督管理局颁 发的两项《医疗器械注册证》，现将有关事项公告如下： 二、对公司的影响及风险提示 本次公司控股子公司获证的医用电子内窥镜图像处理器及电子支气管镜，是 莱美医疗器械研发的内窥镜产品，该产品能直接观察患者图像，有利于临床使用 对患者病症的判断及治疗。此次公司控股子公司产品获证将进一步丰富公司医疗 器械产品种类，满足市场多样化的需求，更将提升公司综合竞争力，对未来经营 将产生积极影响。 1、海南省药品监督管理局颁发的医用电子内窥镜图像处理器《医疗器械注 注册人名称 产品名称 注册证编号 型号、规格 有效期 ...

Core Viewpoint - Recently, Chongqing Laimei Pharmaceutical Co., Ltd. announced that its subsidiary Sichuan Yingrui Pharmaceutical Technology Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of its innovative anti-cancer drug "Nano Carbon Iron Suspension Injection" in combination with standard radiotherapy for solid tumor patients [2] Company Summary - Laimei Pharmaceutical's subsidiary, Sichuan Yingrui, has developed an innovative anti-cancer drug [2] - The drug has received a clinical trial approval notification from the National Medical Products Administration [2] - The clinical trials will focus on the use of the drug in conjunction with standard radiotherapy for patients with solid tumors [2]

Group 1 - The core point of the article is that Zhongheng Group announced the approval of a clinical trial for an innovative anti-cancer drug, "Nano Carbon Iron Suspension Injection," by the National Medical Products Administration of China [2] - The drug is developed by Sichuan Yingrui Pharmaceutical Technology Co., Ltd., a subsidiary of Chongqing Laimei Pharmaceutical Co., Ltd., which is a holding subsidiary of Zhongheng Group [2] - The clinical trial will investigate the combination of Nano Carbon Iron with standard radiotherapy in patients with solid tumors [2]

证券日报网讯12月4日，莱美药业（300006）在互动平台回答投资者提问时表示，截至2025年11月28 日，公司股东户数为33303户。 ...

Core Viewpoint - The company has received ethical approval for the development of Mabalosavir tablets, which is expected to advance clinical trials in accordance with national regulations by June 2025 [1] Group 1 - The company has commissioned an external organization to develop the Mabalosavir tablet project [1] - The clinical trials for Mabalosavir tablets will be conducted in an orderly manner following national clinical trial regulations [1] - The company will continue to monitor the progress of the Mabalosavir tablet clinical trials and fulfill information disclosure obligations as required [1]

Group 1 - China Pacific Insurance has received approval from the financial regulatory authority for Wang Yuhua to serve as a director [1] - Shanghai Bank announced that the regulatory authority has approved Chen Lei's qualification as vice president [2] - Shanghai HuGong has decided to terminate the "Aerospace Equipment Manufacturing Base" fundraising project due to significant changes in project feasibility [3] Group 2 - Dongwang Times plans to reduce its stake by up to 1.20% through share sales [4] - Zhinancun intends to increase its capital by 100 million yuan in its wholly-owned subsidiary, Maigao Securities [5] - Jinxinnong reported a sales revenue of 115 million yuan from pig sales in November [6] Group 3 - Tiantan Biological has completed the Phase III clinical trial of its human prothrombin complex, showing good efficacy and safety for hemophilia B patients [7] - Beijete's subsidiary has signed a framework agreement for equity acquisition to gain control of Yunnan Wenye Nonferrous Metals [8] - Zhongsheng Pharmaceutical's RAY1225 injection has received approval for a new clinical trial indication for treating metabolic-associated fatty liver disease [9] Group 4 - Enhua Pharmaceutical's hydrochloride sulpiride tablets have passed the consistency evaluation for generic drugs [10] - Shenkong Co. plans to invest 60 million yuan in a semiconductor industry fund [11] - Lianhuan Pharmaceutical's subsidiary has received approval for its drug to pass the consistency evaluation for generic drugs [12] Group 5 - Dazhong Transportation has received approval to issue debt financing tools totaling 4.5 billion yuan [13] - Jintian Titanium Industry plans to invest 50 million yuan in an industry merger and acquisition fund [14] - Changchun Gas has committed over 1.7 billion yuan to gas facility upgrades [15] Group 6 - Laimei Pharmaceutical's innovative anti-cancer drug "Nano Carbon Iron" has received approval for clinical trials [16] - Longquan Co. has signed supply contracts worth approximately 50.76 million yuan for nuclear power components [17] - Igor plans to distribute a cash dividend of 1 yuan per 10 shares [18] Group 7 - Xingfa Group's subsidiary has signed a processing agreement for 80,000 tons of lithium iron phosphate [20] - Yunjigroup's director Wang Wanfeng has resigned for personal reasons [21] - Saiseng Pharmaceutical's application for the listing of a new drug has been accepted by the regulatory authority [22] Group 8 - Xinhua Medical has obtained registration certificates for two new medical devices [23] - Chaoying Electronics plans to invest 100 million USD in its Thai subsidiary for an AI circuit board expansion project [24] - Suzhou Planning's application to acquire 100% of Dongjin Aviation has been accepted by the Shenzhen Stock Exchange [25]

Core Viewpoint - Zhongheng Group's subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its innovative anti-cancer drug, "Nano Carbon Iron Suspension Injection," to conduct clinical trials in solid tumor patients [1] Group 1 - The drug is set to be tested in conjunction with standard radiotherapy [1] - The approval marks a significant step in the development of new cancer treatments by the company [1]